Lung cancer is the leading cause of cancer related death worldwide among both, men and woman with about 1.59 million reported deaths in 2012 (1). Two major lung cancer categories are discerned, namely small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) 1 , with the latter comprising ϳ85% of all cases. The two predominant histological NSCLC entities are adenocarcinoma (ADC) and squamous cell carcinoma (SqCC) accounting for ϳ50 and 40% of all lung cancers, respectively (2).Because differentiation of NSCLC subtypes is crucial for the selection of chemotherapy regimens and subsequent molecular test strategies, precise subtyping is paramount. Therapeutic targets such as ALK translocations or activating mutations of the epidermal growth factor receptor (EGFR) have been found almost exclusively in ADC and these patients benefit from the respective molecularly tar-